Background: Lymphoma occurring in patients aged 90 or older is not uncommon, and its incidence is expected to increase over time. Management of these patients is difficult given their underlying fragility and the lack of information regarding this population.
introduction
Over the past century, life expectancy of the overall population has grown impressively in developed countries, and further increases are projected [1] . 'Oldest old' is often defined as people aged 85 and over. However, the 90-and-older (90+) population has been growing more rapidly than those aged 85-89 and other younger age groups among the older population aged 65 and over. According to a report from the US Census Bureau, the 90+ population almost tripled between 1980 and 2010 (increasing from 720 000 to 1.9 million people) in the United States and is projected to more than quadruple again over the next 40 years, rising up to more than 9 million people in 2050 (2% of the total population), when all of the baby boomers reach 85 years of age and above [2] .
In parallel, the incidence of non-Hodgkin lymphoma (NHL) increases with age [3] [4] [5] . In patients 80-84 years, the incidence of NHL is 50 times higher than in patients 20-24 years old [6] .
For these reasons, lymphoma occurring in patients aged 90 or older is not uncommon and its incidence is expected to increase over time.
A few studies have been conducted in patients with lymphoma aged 80 or older [7] [8] [9] [10] . However, in these studies, most of the patients were under 90 years of age (median age: 83-84 years). To our knowledge, no specific data are available regarding patients diagnosed with lymphoma at the age of 90 or older. This particular situation deserves special attention for several reasons. First, as mentioned, the 90+ population is expanding particularly rapidly and lymphoma occurring in these patients will become increasingly frequent. Second, life expectancy at 90 years of age remains fairly long. Today, a 90 years-old person is expected to live on average another 4.6 years (versus 3.2 years in 1929-1931) [11] . Third, lymphoma is a cancer that is usually chemosensitive and sometimes curable, even in elderly patients. Fourth, management of these patients appears particularly delicate due to their underlying fragility. Potential benefit resulting from a treatment remains uncertain at this age. Finally, as mentioned before, no reports are currently available in this population of patients rendering their management even more challenging.
The purpose of the current study is to describe the characteristics, management, outcomes and prognostic factors of patients diagnosed with lymphoma at the age of 90 or over.
patients and methods

study population and disease assessments
We conducted a multicenter retrospective analysis of patients diagnosed with lymphoma at the age of 90 or older in France between January 1990 and June 2012. Fourteen medical centers participated in this study as well as the French network of haematological Cancer Registries (REPIH) (Gironde, Normandy, and Côte d'Or), comprising Reference Centers and communitybased hospitals. Participating centers were members of the Lymphoma Study Association (LYSA). The study was approved by the Institutional Review Boards of Rennes University Hospital (02 October 2012). Staging and therapy were at the discretion of the treating physician. We analyzed 234 patients with Non-Hodgkin (NHL, n = 227) and Hodgkin (HL, n = 7) lymphoma. Following histological/cytological diagnosis, patients were separated into indolent and aggressive NHL for analysis according to the World Health Organization (WHO) classification. Of the 234 cases, 169 had complete data and were entered into a centralized database for further analysis. Descriptive analysis of disease and patient-specific characteristics at diagnosis were obtained. These included lymphoma subtype, Ann Arbor stage, presence of B symptoms (fever >38°C, night sweats, or loss of >10% of body weight), Eastern Cooperative Oncology Group performance status (PS), place of life, complete blood count, serum creatinine, serum albumin, serum lactate dehydrogenase (LDH), and β2-microglobuline (β2 m), prior malignancies, and number of medication at diagnosis. The Charlson index was chosen for retrospectively classifying patients' comorbid conditions [12] .
statistical analysis
Overall survival (OS) was defined as the time from diagnosis until death from any cause or the date of last follow-up while alive. Estimates of survival were computed with the Kaplan-Meier method and tested with the log-rank test. Differences were considered statistically significant when the P-value was 0.05 or less. All variables statistically significant at 5% in the univariate analysis were entered in the multivariate Cox proportional hazard model to assess the independent effect of the prognostic factors on the outcome. Sixteen covariates were included in the univariate analysis. All statistical analyses were carried out using the R software (version 2.14) (R Development Core Team (2011). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. http://www.R-project.org).
results
patient and disease characteristics
We searched in the databases of 14 Medical Centers and the French network of haematological Cancer Registries for patients diagnosed with lymphoma at the age of 90 years or older, between 1990 and 2012. A total of 234 patients were identified of whom 7 (3%) had HL and 227 (97%) had NHL ( Table 1 ). The median age was 92 years (range, 90-100 years); 62% were female (145F/89M). Diffuse large B cell lymphoma (DLBCL) was by the far the most common histological subtype (48% of all patients). The most frequent indolent subtypes were marginal zone lymphoma (9%) and follicular lymphoma (8%). T-cell lymphomas represented 9% of all lymphomas. Other subtypes were rare. Given the limited number of patients with HL, no detailed analysis will be reported for these patients in this study.
Of the 227 cases of NHL, clinical and biological characteristics were available for 166 patients (Table 2) . Diagnosis was made based on histology in 77% of the cases and by cytology in 23% of the cases (these latter cases usually corresponded to blood or bone marrow involvement by an indolent lymphoma, such as marginal zone lymphoma or Waldenstrom disease). Forty-five percent of the patients had histologically or cytologically confirmed extra-nodal disease, most of whom (84%) had DLBCL. Most of the patients (68%) 
management
Among the 166 NHL patients, treatment data were missing for seven patients (4.2%). Decision to treat and the type of treatment were at the discretion of the physician. Results are presented in Table 3 . Overall, 36.5% of the patients received no treatment (or corticosteroids alone), 7.5% received a local therapy (surgery or radiotherapy), and 56% received a systemic therapy (more than half being a polychemotherapy). The percentage of patients receiving a systemic therapy was similar between patients with aggressive and indolent NHL (56.7 versus 54.5%, respectively). However, patients with aggressive NHL received more frequently a polychemotherapy +/-anthracycline (43.2%) whereas patients with indolent NHL received more often a monotherapy (43.6%). Among the 95 patients with B-NHL who received a systemic therapy, 30 patients (32%) were treated with Rituximab, either alone (N = 3) or in combination with a polychemotherapy (N = 27). Most of the patients receiving Rituximab had an aggressive B-NHL (80%). Among NHL patients receiving a treatment (either local or systemic, N = 101), 23% had to be hospitalized due to toxic effect and treatment had to be stopped in 15% of the patients.
About 20% of the patients underwent a geriatric assessment at diagnosis. These patients tended to be less frequently treated than the patients who did not (56.3% versus 65.6%, respectively).
survival
The OS of the 227 patients with NHL is presented in Figure 1 . At the time of analysis, 93% of the patients had died. The median OS was 7.2 months (range, 0-92 months). OS was significantly shorter in patients with aggressive compared with indolent NHL (5.2 months versus 19.4 months, P < 0.001), including for DLBCL (5 months). The reasons of death for 166 NHL patients are presented in supplementary Table S1 , available at Annals of Oncology online. The main cause of death was lymphoma which represented 40% of the cases in the overall population (32% in indolent NHL and 44% in aggressive NHL). Treatment toxic effect accounted for 6% of the deaths. In aggressive NHL, 60% of the deaths were due to lymphoma in the absence of treatment versus 30.4% if the patients were treated. In this latter population, treatment toxic effect accounted for 8.7% of the deaths (data not shown).
prognostic factors
In univariate analysis, we identified a number of factors that affected OS in these patients (Table 4 ). These prognostic factors were different for indolent and aggressive NHL. Factors that were specifically associated with poor survival in indolent NHL were the high number of medications (≥4), anemia (Hb≤10 g/dl), and lymphopenia (≤1100/mm 3 ) (supplementary Figure S1 , available at Annals of Oncology online). Factors that predicted poor survival in aggressive NHL were the place of life (institution), disease dissemination (Ann Arbor stage III-IV), hypoalbuminemia (≤36 g/l), and the absence of treatment (supplementary Figure S2 , available at Annals of Oncology online). The OS was not significantly different between patients with B-NHL (aggressive and/or indolent) who received Rituximab and those who did not (data not shown).
In multivariate analysis, independent factors of death were the high number of medications (HR = 
discussion
To our knowledge, this study is the first that is specifically dedicated to patients with cancer over the age of 90. Lymphoma is an important cancer to consider in this population because it is usually chemosensitive and sometimes curable, even in elderly patients. As a large increase in the number of new lymphoma cases is anticipated in the 90+ population, management of these patients remains particularly delicate due to their underlying fragility. Since no published data were yet available, we conducted this study to analyze how these patients are managed and what may benefit them.
We found that, although different histologic subtypes can be found at this age, there was a large predominance of DLBCL (48.3%), similar to what has been described in the 80+ population (42%-61%) [7] [8] [9] . It should be mentioned that the lymphoma classification has evolved over the 22-year period covered by our study. As a consequence, the more recent pathological entities (such as mantle cell lymphoma, marginal zone lymphoma, and MATL lymphoma) may have been misclassified and thus could be underestimated in our study. In our cohort, there was a predominance of females (62%) although the proportion seemed slightly lower that what has been previously described in the 90+ population (74%) [2] . Most patients were living at home at the time of diagnosis (68%) but a significant proportion of them had comorbidities, including dementia (16%), pre-existing malignancy (24%), and elevated (i.e. ≥4) Charlson index (17%). PS was altered (i.e. ≥2) in 31% of the patients. The proportion of patients with dementia in our study (16%) is less than what has been previously described in the 90+ population where the prevalence was 45% in women and 28% in men [13] . This difference may be due to the fact that patients with dementia are not referred to the hospital as often as other patients, or that very elderly patients are underdiagnosed for dementia in everyday practice unless specific evaluations are carried out.
About two-thirds of the patients received a treatment, either local (7.5%) or systemic (56%). This is less than what has been described in the 80+ population in which 85% of the patients received a treatment, as reported by Thieblemont et al. [9] . Interestingly, despite the age, up to 9.6% of the patients with 
Annals of Oncology original articles
aggressive NHL received a polychemotherapy with anthracycline in our cohort. Twenty percent of the patients underwent geriatric assessment at diagnosis. These patients tended to be less frequently treated than those who did not (56.3% versus 65.6%). This may be due to the fact that frailer patients were more frequently referred for geriatric assessment. In our cohort, treatment toxic effect accounted for 6% of the deaths, which is rather less than the 15.7% previously described in the 80+ population [9] . However, patients in our cohort were treated less frequently and less intensively. As an example, only 6.3% of the overall population received a polychemotherapy with anthracycline compared with 32.2% in the 80+ population [9] . In our cohort, outcome was poor with a median OS of 7.2 months compared with 2.21 years in the 80+ population [9] . The main cause of death was lymphoma. However, the proportion of patients who died from lymphoma (40%) was lower than what has been observed in the 80+ population (57%) [9] , probably because 90+ patients have a higher probability of dying from their comorbidities.
Treatment administration was associated with improved OS in patients with aggressive (supplementary Figure S2D , available at Annals of Oncology online) but not indolent NHL (supplementary Figure S1D , available at Annals of Oncology online). In patients with aggressive NHL who did not receive any treatment or received corticosteroids alone (33.6% of the patients), the median OS was 1.3 months compared with 8.1 months for treated patients (P<0.001). Obviously, patients with more favorable characteristics might have been more likely to receive a treatment. Despite this bias, our observation suggests that treatment may benefit selected patients with aggressive NHL. Although the improvement in median OS appears rather limited (∼7 months) with the treatment, some patients experienced prolonged survival. Indeed, among patients diagnosed with aggressive NHL who received a treatment, 20% remained alive at 2 years and 13% at 4 years. These results suggest that a subset of patients with aggressive NHL may have been cured from their lymphoma.
We have identified several prognostic factors of patients' outcome. Beside 'classical' prognostic factors such as histology, PS and hemoglobin, lymphopenia appeared as a strong prognostic factor in our cohort. This parameter has been previously associated with poor prognosis in various solid cancers and hematological malignancies including Hodgkin lymphoma [14] , T-cell lymphoma [15] , follicular lymphoma [16] , and DLBCL [17] . The reasons for the association of lymphopenia with a worse survival are not well understood. Lymphopenia is associated with an increased risk of complications (including febrile neutropenia and requirement for blood cell and platelet transfusions) [18, 19] . But this is not sufficient to explain the difference in OS. Some studies suggested that lymphopenia may reflect characteristics of both the tumor and the host [20] .
In patients with aggressive NHL, the only two independent prognostic factors were treatment administration and serum albumin. Hypoalbuminemia was present in 27% of the patients and was associated with a significantly shorter OS (2.2 months versus 13.1 months, P<0.001). This finding is in line with the results reported by Peyrade et al. in 80+ patients with DLBCL [10] . In this prospective trial, low serum albumin was found to be the only independent parameter associated with poor outcome [10] . Low serum albumin concentration is associated with malnutrition, cytokine secretion, and advanced disease stage. Thus, serum albumin may reflect the severity of the disease as well as the ability of elderly patients to tolerate a treatment.
Despite inherent biases due to the retrospective nature of our study, several practical conclusions may be drawn from our observations. First, in 90+ patients with indolent NHL, the outcome is not influenced by the treatment. Therefore, the treatment should be reserved to symptomatic patients in order to relieve symptoms. In 90+ patients with aggressive NHL, 44% die of lymphoma and treatment is associated with improved OS. Although median improvement in lifespan is limited in this population (∼7 months), some patients experience prolonged survival suggesting that cure remains possible at that age. Thus, treatment may benefit a subset of patients with aggressive NHL. Management of these patients may be guided by prognostic factors such as hypoalbuminemia (≤36 g/l). This simple and powerful prognostic factor can identify patients with a very poor outcome (median OS∼2 months) for whom a treatment may be useless and possibly deleterious.
Overall, our study shows that lymphoma represents the main cause of death for patients diagnosed with lymphoma at the age of 90 or over. Treatment may improve survival of patients with aggressive NHL (some of whom may be cured) but not indolent NHL. Management of these patients may be guided by prognostic factors identified in this study, based on patients and disease's characteristics. These results warrant further evaluation to prospectively measure the impact of a treatment on both quantity as well as quality of life in this increasingly frequent population of patients.
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